Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

273 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirström K. Borgquist S, et al. Int J Cancer. 2008 Sep 1;123(5):1146-53. doi: 10.1002/ijc.23597. Int J Cancer. 2008. PMID: 18528862
Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence.
Jirström K, Ringberg A, Fernö M, Anagnostaki L, Landberg G. Jirström K, et al. Br J Cancer. 2003 Nov 17;89(10):1920-6. doi: 10.1038/sj.bjc.6601398. Br J Cancer. 2003. PMID: 14612904 Free PMC article.
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
Rydén L, Jönsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström AC, Landberg G, Stål O, Thorstenson S, Nordenskjöld B; South Swedish Breast Cancer Group; South-East Swedish Breast Cancer Group. Rydén L, et al. Eur J Cancer. 2005 Jan;41(2):256-64. doi: 10.1016/j.ejca.2004.06.030. Eur J Cancer. 2005. PMID: 15661551 Clinical Trial.
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis.
Svensson S, Jirström K, Rydén L, Roos G, Emdin S, Ostrowski MC, Landberg G. Svensson S, et al. Oncogene. 2005 Jun 23;24(27):4370-9. doi: 10.1038/sj.onc.1208626. Oncogene. 2005. PMID: 15806151
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
Jirström K, Rydén L, Anagnostaki L, Nordenskjöld B, Stål O, Thorstenson S, Chebil G, Jönsson PE, Fernö M, Landberg G. Jirström K, et al. J Clin Pathol. 2005 Nov;58(11):1135-42. doi: 10.1136/jcp.2005.027185. J Clin Pathol. 2005. PMID: 16254100 Free PMC article. Clinical Trial.
Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers.
Berglund P, Stighall M, Jirström K, Borgquist S, Sjölander A, Hedenfalk I, Landberg G. Berglund P, et al. Cancer Res. 2005 Nov 1;65(21):9727-34. doi: 10.1158/0008-5472.CAN-04-3984. Cancer Res. 2005. PMID: 16266993
Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
Kronblad A, Jirström K, Rydén L, Nordenskjöld B, Landberg G. Kronblad A, et al. Int J Cancer. 2006 May 15;118(10):2609-16. doi: 10.1002/ijc.21676. Int J Cancer. 2006. PMID: 16381002
273 results
Jump to page
Feedback